A prospective study sought to determine the value of geriatric assessment in patients with non-Hodgkin lymphoma, compared with assessment based on chronological age.
Time to next treatment was significantly longer with brentuximab vedotin.
A single-institution study determined the effect of a novel nursing practice on incidence of PICC-UEDVT, outcomes, and satisfaction with care in patients with NHL.
Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.
Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.
The antibody-drug conjugate demonstrated durable antitumor activity in heavily pretreated patients.
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
The biosimilar has been approved for the treatment of Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
